September 3, 2024 7:30 am EDT

JERSEY CITY, N.J. – September 3, 2024 – Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that Daniel Karp has been appointed to the new position of Executive Vice President, Corporate Development, effective September 9, 2024. Previously, Mr. Karp led the business development team as the Chief Business Development Officer.

As an independent company, Organon has completed nine business development deals under Mr. Karp’s leadership. Through these efforts, Mr. Karp and his team have identified important assets and transactions that provide solutions to unmet patient needs, helping Organon expand its portfolio and advance its mission in women’s health.

“As Chief Business Development Officer, Daniel has been critical to identifying and executing transactions responsible for driving Organon’s growth and pipeline, including assets that could, if successful, offer differentiated new options for women,” said Kevin Ali, CEO. “In this new role, Organon will continue to benefit from his vision and business development strategy, creating both near- and long-term growth opportunities for our business.”

Prior to joining Organon, Mr. Karp served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for R&D, and VP, Head of BD for Vaccines, Oncology, and Consumer Healthcare. His extensive experience includes mergers and acquisitions, licensing, and collaborations across numerous therapeutic areas and all stages of therapeutic development.

“It’s been a privilege to be part of the team who launched Organon as a standalone company, and guiding the company’s business development strategy,” Mr. Karp said. “I’m looking forward to continuing our efforts of expanding the company’s pipeline and portfolio across our women’s health, biosimilars and established brands.”

Mr. Karp has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania.

About Organon

Organon is an independent global healthcare company with a strategy to help improve the health of women throughout their lives. Organon’s diverse portfolio offers more than 60 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.